Corcept Therapeutics is on a roll the last month, because it had been able to establish two key events from its pipeline. For starters, it was able to report that it had met the primary endpoint of its pivotal...
Cassava Sciences recently reported results from its second of two phase 3 studies known as REFOCUS-ALZ. This was a huge study as it recruited a total of 1,125 patients. It was noted that the co-primary endpoints of this late-stage...
Lexicon Pharmaceuticals was able to establish a deal with Novo Nordisk, whereby the big pharma obtained an exclusive, worldwide license for LX9851 for the treatment of patients with Obesity. This drug candidate is a small molecule inhibitor of Acyl-CoA...
